News Archives

News Archives

Avivagen Announces Q2 Financial Results

Ottawa, ON / TNW-Accesswire / June 5, 2018 / – – Avivagen Inc. (TSXV:VIV)(“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance, today reported its financial results for Q2, 2018.  Unless otherwise …Read More

Avivagen Announces Distribution in China for Vivamune

Ottawa, ON / TNW-Accesswire / June 1, 2018 / – Avivagen Inc. (TSXV:VIV)(“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance, is pleased to announce that it has made its first sale …Read More

Avivagen Announces Approval of OxC-beta™ For Use in Livestock in New Zealand

Ottawa, ON / TNW-Accesswire / May 30, 2018 / – – Avivagen Inc. (TSXV:VIV)(“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance, is pleased to announce that it has received GRAS (Generally …Read More

Avivagen to Pursue Regulatory Approval in Mexico

Ottawa, ON / TNW-Accesswire / May 25, 2018 / – Avivagen Inc. (TSXV:VIV)(“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance, announces that it has retained Meyenberg International Group (MIG) as its …Read More

Avivagen Announces Drawdown from Credit Facility

Ottawa, ON / TNW-Accesswire / May 22, 2018 / – Avivagen Inc. (TSXV:VIV, OTC Pink:CHEXF) (“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance, announces it has drawn down CAD $800,000 from …Read More

Avivagen Announces the Issuance of Shares

Ottawa, ON / TNW-Accesswire / May 2, 2018 / – Avivagen Inc. (TSXV:VIV, OTC Pink:CHEXF) (“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance, announces the issuance of common shares to Mr. …Read More